New York, NY, March 19, 2019 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Myasthenia Gravis Market by Diagnosis (Edrophonium Tests, Blood Tests, Pulmonary Function Tests, Electrodiagnostic, Imaging, and Others), by Treatment (Surgery, Medication, Plasmapheresis, and Intravenous Immunoglobulin, Autologous Hematopoietic Stem Cell Transplantation (HSCT), and others), and by End-User (Hospitals, Academic Research Institutes, Clinics, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global myasthenia gravis market was valued at approximately USD 1,066 million in 2018 and is expected to generate around USD 2,091 million by 2025, at a CAGR of around 10.2% between 2019 and 2025.

Myasthenia Gravis is an autoimmune neuromuscular disorder that leads to serious muscle weakness. It is caused due to an error in the transmission of nerve impulses to muscles. It generally occurs when the normal communication between nerve and muscle disrupts at the neuromuscular joints. In this disorder, the antibodies present in the body destroy the receptor for acetylcholine at the neuromuscular joint, which, in turn, prevents the muscles from contracting and performing normal functions. There is no permanent cure for this condition and it affects one’s quality of life. The treatment helps in the improvement of the quality of life and life expectancy remains normal.

Browse through 54 Tables & 27 Figures spread over 110 Pages and in-depth TOC on “Global Myasthenia Gravis Market: By Drug Type, Size, Industry Share, Trends, Growth, Segments, Analysis and Forecast 2018–2025”.

Request Free Sample Report of Global Myasthenia Gravis Market Report @ https://www.zionmarketresearch.com/sample/myasthenia-gravis-market

As per the Myasthenia Gravis Foundation of America 2015, there were around 14 to 20 myasthenia gravis cases per 100,000 people, approximating nearly 36,000 to 60,000 cases of myasthenia gravis in the U.S. Furthermore, an increase in the number of autoimmune disorders coupled with strong product pipeline is also expected to drive the growth of the global myasthenia gravis market over the estimated period. The increase in healthcare expenditure, robust healthcare infrastructure, and growth in the awareness about the ailment among people is also anticipated to drive the growth of the global myasthenia gravis market. Moreover, increased adoption of novel therapies along with favorable reimbursement policies in developed economies will promote the myasthenia gravis market globally. Increased research and development activities and massive investments are expected to create new growth opportunities in the myasthenia gravis market. However, the high treatment costs, limited availability of FDA-approved drugs may inhibit the growth of the myasthenia gravis market in the future.

The global myasthenia gravis market is segmented on the basis of treatment, diagnosis, and end-user. By diagnosis, the market is segmented into edrophonium tests, blood tests, pulmonary function tests, electrodiagnostic, imaging, and others. Blood tests are expected to hold the major market share. By treatment, the market is segmented into surgery, medication, plasmapheresis and intravenous immunoglobulin, autologous hematopoietic stem cell transplantation (HSCT), and others. The medication segment is expected to contribute majorly toward the global market over the forecast timespan. By end-user, the market is segmented into hospitals, academic research institutes, clinics, and others. Hospitals are expected to hold the major market share in the future.

Download Free Report PDF Brochure: https://www.zionmarketresearch.com/requestbrochure/myasthenia-gravis-market

North America is expected to lead the global myasthenia gravis market over the forecast time period due to the increased adoption of novel therapies, increase in awareness among the people, favorable reimbursement policies, the presence of developed countries, such as the U.S. and Canada, and robust healthcare infrastructure. As per the Myasthenia Gravis Foundation of America 2015, there were around 14 to 20 myasthenia gravis cases per 100,000 people in the U.S. Furthermore, the high adoption rate of novel therapies and treatment and advanced healthcare facilities and infrastructure are expected to further promote the North American myasthenia gravis market over the forecast time period.

Europe is expected to be the second largest market over the forecast time period and closely follow North America in terms of revenue. The presence of advanced research and development facilities and technological advancement are expected to propel the region’s myasthenia gravis market in the years ahead.

Browse the full “Myasthenia Gravis Market by Diagnosis (Edrophonium Tests, Blood Tests, Pulmonary Function Tests, Electrodiagnostic, Imaging, and Others), by Treatment (Surgery, Medication, Plasmapheresis and Intravenous Immunoglobulin, Autologous Hematopoietic Stem Cell Transplantation (HSCT), and others), and by End-User (Hospitals, Academic Research Institutes, Clinics, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025” Report at https://www.zionmarketresearch.com/report/myasthenia-gravis-market

The Asia Pacific myasthenia gravis market is expected to grow rapidly over the forecast time period, owing to the presence of developing economies such, as India and China, the presence of strong healthcare infrastructure, increased affordability, and substantial technological advancements.

Latin America and the Middle East and Africa are expected to expand considerably over the forecast time period, owing to the increasing awareness among the regional population, rapid development in medical facilities, economic growth, and favorable government initiatives.

Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/myasthenia-gravis-market

Some key players of the global myasthenia gravis market are Novartis Pharmaceuticals Corporation, AbbVie Inc., Biogen Inc., Pfizer, Valeant Pharmaceuticals International, Bristol-Myers Squibb Company, F. Hoffmann Roche La Ltd., GlaxoSmithKline, RPG Life Sciences, and Grifols SA, among others.

Request customized copy of report @ https://www.zionmarketresearch.com/custom/3927

This report segments the global myasthenia gravis market as follows:

Global Myasthenia Gravis Market: Diagnosis Analysis

  • Edrophonium Tests
  • Blood Tests
  • Pulmonary Function Tests
  • Electrodiagnostic
  • Imaging
  • Others

Global Myasthenia Gravis Market: Treatment Analysis

  • Surgery
  • Medication
  • Plasmapheresis and Intravenous Immunoglobulin
  • Autologous Hematopoietic Stem Cell Transplantation (HSCT)
  • Others

Global Myasthenia Gravis Market: End-User Analysis

  • Hospitals
  • Academic Research Institutes
  • Clinics
  • Other

Global Myasthenia Gravis Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Related Reports:

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_research

Blog: http://zmrindustryjournal.us  | http://zmrresearchnews.us | http://zmrmarketjournal.com  | https://zmrnewsjournal.us | http://zmrnewsmagazine.com | https://zmrnewsblog.com

Contact Us:

Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com

Website: https://www.zionmarketresearch.com

Blog: http://zmrblog.com